Abstract：Objective To explore the effects of Ranibizumab intraocular injection in treating wet age-related macular degeneration(wAMD).M ethods 92(100 eyes)patients with wAMD in our hospital from January 2012 to January 2015 were selected and used Ranibizumab intraocular injection.Data of best corrected visual acuity,intraocular pressure, optical coherence tomography,indocyanine green choroidal angiography and multi focus ERG were recorded before treatment and after treatment for 1month,3,6 and 12months.The clinial effects of Ranibizumab in treating wAMD were evaluated.Results Before treatment,centralmacular thickness(CMT)by usingOCTmeasurementhad statisticalsignificance compared with CMT that after treatment for 1 month,3,6 and 12 months(P＜0.01).After treatment 12 months,41 eyes stopped to leak fluid,and no more leakage increased.The leakage area before treatment,after treatment for 3,6 and 12 months was respectively(11.34±6.10)mm2,(9.77±5.77)mm2,(8.76±5.46)mm2and(6.80±4.88)mm2,all of the leakage area obvious decreased after treatment,and the difference was statistical significance compared with before treatment (P＜0.05).Conclusion Using Ranibizumab in treating wAMD can alleviate macular edema effectively and improve the vision of patients and with little adverse effects.
Park JH，Woo SJ，Ha YJ，et al.Macular capillary blood flow in patients with diffuse diabetic macular edema without vitreomacular traction[J].Ophthalmic Res，2009，42（2）：73-80.
Noma H，Funatsu H，Mimura T，et al.Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion[J].Br JDphthalmol，2011，95（6）：788-792.
[15]
Noma H，Funatsu H，Mimura T，et al.Vascular endothelial growth factor receptor-2 in macular oedema with retinal vein occlusion[J].Ophthalmic Res，2012，48（1）：56-58.
[16]
Mete A，SaygiliO，Gungor K，etal.Does ranibizumab（Lueenfis）change retrobulbar blood flow in patients with neovascular age-related macular degeneration?[J].Ophthalmic Res，2012，47（3）：141-145.
京公网安备 11010502046607号